Reckitt Benckiser Group (OTCMKTS:RBGLY) Lifted to “Strong-Buy” at Citigroup

Citigroup upgraded shares of Reckitt Benckiser Group (OTCMKTS:RBGLY) to a strong-buy rating in a report issued on Tuesday, Zacks.com reports.

Several other research analysts have also weighed in on the stock. JPMorgan Chase & Co. lowered shares of Reckitt Benckiser Group from an overweight rating to a neutral rating in a research note on Thursday, August 29th. UBS Group raised shares of Reckitt Benckiser Group to a strong-buy rating in a research report on Wednesday, September 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of Hold.

Reckitt Benckiser Group Price Performance

OTCMKTS:RBGLY opened at $12.06 on Tuesday. Reckitt Benckiser Group has a 1-year low of $10.24 and a 1-year high of $15.03. The business’s 50-day moving average price is $11.55 and its two-hundred day moving average price is $11.30.

Reckitt Benckiser Group Cuts Dividend

The business also recently declared a dividend, which was paid on Monday, September 23rd. Stockholders of record on Monday, August 5th were issued a $0.1915 dividend. The ex-dividend date was Monday, August 5th.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.